|drug210||COVID-19 PCR and Serology Wiki||1.00|
|D020181||Sleep Apnea, Obstructive NIH||1.00|
|D012891||Sleep Apnea, NIH||1.00|
There is one clinical trial.
Covid-19 infection is an on-going pandemic with worse diagnosis in adults with comorbid conditions such as hypertension and cardiopulmonary diseases. Obstructive sleep apnea (OSA) is common in those comorbidities and may contribute to worse prognosis for the Covid-19 cases.
Description: Defined as a decline of 2 categories from admission on a 7-category ordinal scaleMeasure: The rate of clinical improvement Time: 28 days
Description: Time to hospital discharge, ICU discharge, weaning from intubation, weaning from supplemental oxygen, incident pneumonia, ARDS, in-hospital mortalityMeasure: Clinical status Time: 7, 14, 21, 28 days
Description: Re-analysis of the correlation of obstructive sleep apnea (objectively verified) severity in terms of apnea-hypopnea index and oxygenation levels with the primary and secondary outcomes as described above (the rate of clinical improvement defined as a decline of 2 categories from admission on a 7-category ordinal scale; time to hospital discharge, ICU discharge, weaning from intubation, weaning from supplemental oxygen, incident pneumonia, ARDS, in-hospital mortality as well as with the lung function, CO-diffusion capacity, cardiac function, CT thorax pathologies, biomarkers (cytokines, polymorphisms) and IgG-antibodies after 4 months.Measure: Long-term outcomes Time: 4 months after the initial hospital admission